A comprehensive review on the dynamics of protein kinase CK2 in cancer development and optimizing therapeutic strategies

被引:0
|
作者
Ghani, Muhammad Usman [1 ,2 ]
Shi, Junbo [1 ,2 ]
Du, Yi [1 ,2 ]
Zhong, Liping [4 ]
Cui, Hongjuan [1 ,2 ,3 ]
机构
[1] Southwest Univ, Med Res Inst, Chongqing 400715, Peoples R China
[2] Southwest Univ, State Key Lab Resource Insects, Chongqing 400715, Peoples R China
[3] Jinfeng Lab, Chongqing 401329, Peoples R China
[4] Guangxi Med Univ, State Key Lab Targeting Oncol, Nanning 530021, Guangxi, Peoples R China
基金
美国国家科学基金会;
关键词
CK2; Signal transduction; Apoptosis; Hallmark of cancer; Therapy; NF-KAPPA-B; BIOLOGICAL EVALUATION; SIGNALING PATHWAY; CELLS; DEGRADATION; ACTIVATION; CK2-ALPHA; TARGETS; RNAI;
D O I
10.1016/j.ijbiomac.2024.135814
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protein kinase 2 (CK2) is an enzyme ubiquitously present and exhibits extensive kinase activity. It has been strongly linked to tumor progression through the abnormal phosphorylation of key proteins. Research has consistently demonstrated that CK2 is deregulated in various cancer types, with enhanced protein expression and nuclear distribution in tumor cells. CK2 plays a crucial role in a complex network that promotes cell infiltration, migration, proliferation, apoptosis, and cancer progression through multiple pathways, including PI3K/AKT, JAK2/STAT3, ATF4/CDKN1, and HSP90/Cdc37. In addition to its role in cancer growth, there is mounting evidence that CK2 may also affect the immunological dynamics of cancer by altering immune cell functions within the tumor microenvironment, thus facilitating tumor immune evasion. Recent research has increasingly focused on CK2, recognizing it as a therapeutic objective for oncological interventions. This review will critically examine the structure and signaling pathways of CK2, highlighting the significance of further research aimed at enhancing our understanding of the CK2 machinery. Finally, we conclude by refining therapeutic options, notably transitioning from non-pharmacological techniques to strategic CK2 inhibitor use. This development shortens the path to the desired outcome, establishing a pioneering standard in cancer therapy.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Recent Advances in Protein Kinase CK2, a Potential Therapeutic Target in Cancer
    Nipun, V. B.
    Amin, K. A.
    RUSSIAN JOURNAL OF BIOORGANIC CHEMISTRY, 2022, 48 (05) : 919 - 931
  • [2] Recent Advances in Protein Kinase CK2, a Potential Therapeutic Target in Cancer
    V. B. Nipun
    K. A. Amin
    Russian Journal of Bioorganic Chemistry, 2022, 48 : 919 - 931
  • [3] Protein kinase CK2
    Pinna, LA
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 1997, 29 (04) : 551 - 554
  • [4] Protein kinase CK2 inhibitors: a patent review
    Cozza, Giorgio
    Pinna, Lorenzo A.
    Moro, Stefano
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (09) : 1081 - 1097
  • [5] The Role of Protein Kinase CK2 in Glioblastoma Development
    Ji, Haitao
    Lu, Zhimin
    CLINICAL CANCER RESEARCH, 2013, 19 (23) : 6335 - 6337
  • [6] Dependence of HSP27 cellular level on protein kinase CK2 discloses novel therapeutic strategies
    Borgo, Christian
    Vilardell, Jordi
    Bosello-Travain, Valentina
    Pinna, Lorenzo A.
    Venerando, Andrea
    Salvi, Mauro
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2018, 1862 (12): : 2902 - 2910
  • [7] Protein kinase CK2 – diverse roles in cancer cell biology and therapeutic promise
    Janeen H. Trembley
    Betsy T. Kren
    Muhammad Afzal
    George A. Scaria
    Mark A. Klein
    Khalil Ahmed
    Molecular and Cellular Biochemistry, 2023, 478 : 899 - 926
  • [8] Protein kinase CK2: a challenge to canons
    Pinna, LA
    JOURNAL OF CELL SCIENCE, 2002, 115 (20) : 3873 - 3878
  • [9] Protein Kinase CK2 in Health and DiseaseCellular functions of Protein kinase CK2: a dynamic affair
    O. Filhol
    C. Cochet
    Cellular and Molecular Life Sciences, 2009, 66 : 1830 - 1839
  • [10] Regulation of cancer progression by CK2: an emerging therapeutic target
    Hussain, Shakeel
    Guo, Yilei
    Huo, Yu
    Shi, Juanjuan
    Hou, Yongzhong
    MEDICAL ONCOLOGY, 2024, 41 (05)